A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

NCT07589595 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

350

Enrollment

INDUSTRY

Sponsor class

Conditions

Cognitive Dysfunction
Lewy Body Disease
Synucleinopathies
Amyloid

Interventions

DRUG: Donanemab
DRUG: Placebo

Sponsor

Eli Lilly and Company